PROHEALING PIEZOELECTRIC COATINGS

• US 20160184491A1
• Filed: 03/07/2016
• Published: 06/30/2016
• Est. Priority Date: 08/07/2007
• Status: Abandoned Application

• Current Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories Incorporated)
• Inventors: Hossainy, Syed Faiyaz Ahmed, Trollsas, Mikael, Kleiner, Lothar Walter
• Application Number:
  US15/063,367
• Publication Number:
  US 20160184491A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2420/02 Methods for coating medical devices
• CPC Class Codes: A61L 2420/04 Coatings containing a composite material such as inorganic/organic, i.e. material comprising different phases
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: B05D 3/14 by electrical means
• CPC Class Codes: C08F 114/22 Vinylidene fluoride
• CPC Class Codes: C08F 14/22 Vinylidene fluoride
• CPC Class Codes: C08F 214/22 Vinylidene fluoride
• CPC Class Codes: C08F 214/28 Hexyfluoropropene

Abstract

Provided herein is a prohealing piezoelectric coating and the method of making and using the same.

Claims

1. A coating on an implantable medical device comprising at least one polarized piezoelectric polymer or material.

2. The coating of claim 1, comprising a polarized piezoelectric polymer.

3. The coating of claim 2, wherein the piezoelectric polymer is selected from poly(vinylidene fluoride) (PVDF), poly(vinylidene fluoride-co-hexafluoropropylene) (PVDF-HFP), poly(vinylidene fluoride-co-trifluoroethylene) (PVDF-TrFE), poly(vinylidene fluoride-co-tetrafluoroethylene) (PVDF-TFE), or combinations thereof.

4. The coating of claim 2, wherein the piezoelectric polymer is a copolymer comprising units derived from fluoro vinyl monomers.

5. The coating of claim 1, comprising a polarized piezoelectric material.

6. The coating of claim 5, wherein the piezoelectric material comprises a piezoelectric ceramic or a piezoelectric polymer-ceramic composite.

7. The coating of claim 6, wherein the polymer-ceramic composite comprises a multi-layer composite containing a polymer and a piezoelectric ceramic.

8. The coating of claim 7, wherein the polymer is selected from PVDF, PVDF-HFP, PVDF-TrFE, PVDF-TFE, or combinations thereof.

9. The coating of claim 6, wherein the piezoelectric ceramic is selected from lead zirconium titanate (PZT), lead scandium tantalate, barium strontium titanate, lead magnesium niobate, or combinations thereof.

10. The coating of claim 6, wherein the piezoelectric ceramic is selected from Pb(xZr,(1-x)Ti)O₃, BaTiO₃, PbZrO₃, PbTiO₃, PbNb₂O₆, (Pb,Ca)TiO₃, (Pb,Sm)TiO₃, Pb(NbO₂)₂/PbTiO₃, (1-x)Pb(Mg_1/3Nb_2/3)O₃-xPbTiO₃, (1-x-y)Pb(Zn_1/3Nb_2/3)O₃-xPbTiO₃-yBaTiO₃, and (1-x-y)Pb(Zn_1/3Nb_2/3)O₃-xBaTiO₃-yPbTiO₃, xPZN-(1-x)PMN, xPMN-(1-x)PZT, PNN-PZ-PT, xPZN-(1-x)PZT, or combinations thereof.

11. The coating of claim 1, wherein the implantable medical device is stent.

12. The coating of claim 1, further comprising at least one bioactive agent.

13. The coating of claim 12, wherein the bioactive agent is selected from paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), biolimus, tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), γ

-hiridun, clobetasol, pimecrolimus, imatinib mesylate, midostaurin, prodrugs thereof, co-drugs thereof, and combinations thereof.

14. The coating of claim 1, further comprising a chemo-attractant for endothelial cells.

15. The coating of claim 11, wherein the chemo-attractant is RGD or cyclic RGD peptide.